Skip to main
PRQR
PRQR logo

ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics (PRQR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProQR Therapeutics NV is positioned favorably due to its promising Axiomer RNA base-editing platform, which is anticipated to yield positive clinical data from its first-in-human studies, potentially enhancing the company's valuation. Furthermore, the company’s management maintains confidence in its financial stability, with a cash position sufficient to sustain operations into mid-2027, thereby allowing for continued development of its RNA-based therapeutics pipeline. The possibility of expedited clinical advancements could lead to significant stock price appreciation as proof of concept data emerges from human trials.

Bears say

ProQR Therapeutics NV reported a significant increase in net loss for the quarter, reaching -€12.2 million with an earnings per share (EPS) of (€0.12), compared to a loss of -€2.7 million and an EPS of (€0.03) for the same period in 2024, highlighting ongoing financial challenges. The company is heavily reliant on the outcomes of its future Phase Ib/II/III clinical studies, where negative results could exert downward pressure on its stock performance. Furthermore, potential advancements in alternative treatment methods for the diseases addressed by ProQR could jeopardize the competitiveness of its existing therapies, introducing additional uncertainty to its market position.

ProQR Therapeutics (PRQR) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProQR Therapeutics (PRQR) Forecast

Analysts have given ProQR Therapeutics (PRQR) a Buy based on their latest research and market trends.

According to 7 analysts, ProQR Therapeutics (PRQR) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProQR Therapeutics (PRQR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.